cbdMD Q3 Gaap EPS $(0.15) Beats $(0.62) Estimate, Sales $5.17M Beat $4.93M Estimate
Portfolio Pulse from saritha@benzinga.com
cbdMD (AMEX:YCBD) reported Q3 GAAP EPS of $(0.15), beating the $(0.62) estimate by 75.81%. Sales were $5.17M, surpassing the $4.93M estimate by 4.95%. Despite the positive earnings surprise, sales decreased by 15.44% compared to the same period last year.
August 14, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
cbdMD reported better-than-expected Q3 GAAP EPS of $(0.15), significantly beating the $(0.62) estimate. Sales also surpassed expectations at $5.17M, though they were down 15.44% year-over-year.
The significant beat on EPS and sales estimates is likely to have a positive short-term impact on YCBD's stock price. However, the year-over-year decline in sales may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100